A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 2005-2015

  Giaccone, Giuseppe ^a   Linn, Sabine C ^a   Welink, Jan ^a   Catimel, Giles ^b   Stieltjes, Hans ^a   Van Der Vijgh, Wim J F ^a   Eeltink, Corien ^a   Vermorken, Jan B ^a   Pinedo, Herbert M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DOXORUBICIN; VALSPODAR;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG CLEARANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MULTIDRUG RESISTANCE; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS;

EID: 0030666026     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Pinedo, H. M., and Giaccone, G. P-glycoprotein: a marker of cancer cell behavior. New Engl. J. Med., 333: 1417-1419, 1995.
2. Giaccone, G., and Pinedo, H. M. Reversal of MDR in solid tumors. In: S. Gupta and T. Tsuruo (eds.). Multidrug Resistance in Cancer Cells: Molecular, Biochemical, Physiological and Biological Aspects, pp. 473-491. Chichester, United Kingdom: John Wiley & Sons, 1996.
3. Gaveriaux, C., Boesch, D., Boelsterli, J. J., Bollinger, P., Eberle, M. K., Hiestand, P., Payne, T., Traber, R., Wenger, R., and Loor, F. Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and nonimmunosuppressive derivatives. Br. J. Cancer, 60: 867-871, 1989.
4. Boesch, D., Gaveriaux, C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, A., and Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51: 4226-4233, 1991.
5. Twentyman, P. R., and Bleehen, N. M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur. J. Cancer, 27: 1639-1642, 1991.
6. Keller, R. P., Altermatt, H. J., Nooter, K., Porschmann, G., Laissue, J. A., Bollinger, P., and Hiestand, P. C. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50: 593-597, 1992.
7. Watanabe, T., Naito, M., Oh-hara, T., Itoh, Y., Cohen, D., and Tsuruo, T. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models. Jpn. J. Cancer Res., 87: 184-193, 1996.
8. Jachez, B., Nordmann, R., and Loor, F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J. Natl. Cancer Inst. (Bethesda), 85: 478-483, 1993.
9. Erlichman, C., Moore, M., Thiessen, J. J., Kerr, I. G., Walker, S., Goodman, P., Bjarnason, G., DeAngelis, C., and Bunting, P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res., 53: 4837-4842, 1993.
10. Bartlett, N. L., Lum, B. L., Fisher, G. A., Brophy, N. A., Ehsan, M. N., Halsey, J., and Sikic, B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol., 12: 835-842, 1994.
11. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
12. Maessen, P. A., Pinedo, H. M., Mross, K. B., and van der Vijgh, W. J. F. Improved method for the determination of 4′-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography. J. Chromatogr., 417: 339-346, 1987.
13. Siegel, S. Nonparametric Statistics for Behavioral Sciences. Tokyo: McGraw-Hill Kogakusha Ltd., 1956.
14. Fisher, G. A., Lum, B. L., Hausdorff, J., and Sikic, B. I. Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer, 32A: 1082-1088, 1996.
15. Lush, R. M., Meadows, B., Fojo, A. T., Kalafsky, G., Smith, H. T., Bates, S., and Figg, W. D. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. J. Clin. Pharm., 37: 123-128, 1997.
16. Erlichman, C., Moore, M., Thiessen, J., DeAngelis, C., Goodman, P., and Manzo, J. A Phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR). Anticancer Drugs, 5 (Suppl. 1): 42, 1994.
17. Chaudhary, P., and Roninson, I. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 56: 85-94, 1991.
18. Colombo, T., Zucchetti, M., and D'Incalci, M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J. Pharmacol. Exp. Ther., 269: 22-27, 1994.
19. Gonzalez, O., Colombo, T., De Fusco, M., Imperatori, M., Zucchetti, M., and D'Incalci, M. Changes in doxorubicin distribution and toxicity in mice prctreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother. Pharmacol., 36: 335-340, 1995.
20. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., and Riele, H. P. Disruption of the mouse mdr1a P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994.
21. Kerr, D. J., Graham, J., Cummings, J., Morrison, J. G., Thompson, G. G. Brodie, M. J., and Kaye, S. B. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol., 18: 239-242, 1986.
22. Fedeli, L., Colozza, M., Boschetti, E., Sabalich, A., Aristei, C., Guerciolini, R., Del Favero, A., Rossetti, R., Tonato, M., and Rambotti, P. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer (Phila.), 64: 1805-1811, 1989.
23. Wilson, W. H., Jamis-Dow, C., Bryant, G., Balis, F. M., Klecker, R. W., Bates, S. E., Chabner, B. A., Steinberg, S. M., Kohler, D. R., and Wittes, R. E. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J. Clin. Oncol., 13: 1985-1994, 1995.
24. Lum, B. L., Kaubish, S., Yahanda, A. M., Adler, K. M., Jew, L., Ehsan, M. N., Brophy, N. A., Halsey, J., Gosland, M. P., and Sikic, B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol., 10: 1635-1642, 1992.
25. Wacher, V. J., Wu, C. Y., and Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 13: 129-134, 1995.
26. Speeg, K. V., and Maldonado, A. L. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol., 34: 133-136, 1994.
27. van der Valk, P., van Kalken, C. K., Ketelaars, H., Broxterman, H. J., Scheffer, G., Kuiper, C. M., Tsuruo, T., Lankelma, J., Meijer, C. J., and Pinedo, H. M. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann. Oncol., 1: 56-64, 1990.
28. Vikers, A. E. M., Meyer, E., Danneker, R., Keller, B., Tynes, R. E., and Maurer, G. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125. Am. Soc. Pharmacol. Exp. Ther., 23: 321-326, 1995.
29. Böhme, M., Büchler, M., Müller, M., and Keppler, D. Differential inhibition by cylosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett., 333: 193-196, 1993.
30. Ozols, R. F., Willson, J. K. V., Weltz, M. D., Grotzinger, K. R., Myers, C. E., and Young, R. C. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res., 40: 4109-4112, 1980.
31. Olson, R. D., Mushlin, P. S, Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., and Boucek, R. J. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. USA, 85: 3585-3589, 1988.
32. Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H., 61nd Bleehen, N. M. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol., 14: 610-618, 1996.
33. Yahanda, A. M., Adler, K. M., Fischer, G. A., Brophy, N. A., Halsey, J., Hardy, R. I., Gosland, M. P., Lum, B. L., and Sikic, B. I. A Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol., 10: 1624-1634, 1992.
34. Lemaire, M., Buelisauer, A., Guntz, P., and Sato, H. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reserving cyclosporin, in rats. Cancer Chemother. Pharmacol., 38: 481-486, 1996.